The QMN Weekly Bulletin

Hospira is looking into a supplier glass defect following consumer complaints and a Health Canada warning to physicians not to use three lots of its cancer treatment paclitaxel injection, 300 mg/50 mL. Complaints to the company from outside Canada described particles embedded in the glass vial, rust-like marks on the vial and particles in the solution, the agency said. Hospira to date has not received any adverse event complaints for the lots.
Drug Industry Daily